• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·600252.SS
Share

Guangxi Wuzhou Zhongheng Group Co., Ltd Stocks

CN¥ 2.22Last Updated 15.07.2026

Issuer Rating

3/7
Performance

Poor

Risk

Limited

Recommendation

Sell

Market Cap

CN¥ 925.74M

CN¥ 2.22
Key Takeaways

Risk factor

Low price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Guangxi Wuzhou Zhongheng Group Co., Ltd., operating from Wuzhou, China, specializes in the research, development, manufacturing, and distribution of pharmaceutical products across the nation. The company's diverse range of medicinal preparations includes pills, capsules, injections, and tablets, formulated to address various health concerns such as cardiovascular and cerebrovascular disorders, physical injuries, gynecological conditions, and respiratory ailments. In addition to its core pharmaceutical business, Guangxi Wuzhou Zhongheng Group also produces health food items, notably under its DOUBLE MONEY brand. Furthermore, its offerings encompass health-oriented functional beverages, various forms of turtle paste (including smokable and jelly types), and other related wellness products.

Company Valuation

Overvalued
2/7

Based on key historical and expected multiples, the stock is overvalued relative to its peers. In particular, the stock is overvalued on P/FCF.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

15.07.2026 16:00

"There Aren't Enough IT Budgets to Go Around": What Does IBM's Historic Plunge Mean for the Stock Market?

15.07.2026 15:46

Morning in New York: New inflation data will set the tone for trading

15.07.2026 14:33

Where to Invest $1,000 Right Now: 4 Stocks to Consider in the Third Quarter

15.07.2026 13:49

Apple has found a startup that reduces the size of AI models. This could help it improve Siri

15.07.2026 11:45

HSBC has named Kaspi shares its top pick for July. Why does it expect them to rise by a third?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026